Antibody startup Cell Surface Bio emerges from stealth to transform the antibody reagent market

Emerging from stealth mode, Cell Surface Bio (CSB),  has launched VeRSaMAb research antibodies with the vision of delivering "antibodies that always work," answering the call of the scientific community for reliable reagents with uncompromising quality.

Providing monoclonal antibodies that are extensively validated, recombinantly cloned, and exquisitely specific, CSB is being built to transform the >$10 billion antibody reagent market where currently half of the antibodies sold do not work as designed. VeRSaMAbs are produced at CSB and extensively characterized to ensure reliable results in customers' experiments every time.

Benjamin Doranz, Co-founder, Cell Surface Bio: "Cell Surface Bio was created by scientists for scientists. Every researcher I've met, myself included, knows the frustration of time wasted in the lab running experiments with antibodies that simply do not work. Our goal is to provide researchers with only the highest quality monoclonal antibodies that are fully validated and engineered for the highest sensitivity of detection, so that they always work in our customers' experiments."

A spin-out of Philadelphia's Integral Molecular, CSB leverages the parent company's 20+ years of expertise developing and characterizing therapeutic antibodies that target complex and conserved proteins on the cell surface. CSB's VeRSaMAbs are derived using the same next-generation platform used to isolate best-in-class drugs, featuring high-throughput mRNA immunization, Lipoparticles™ (virus-like particles) for high-concentration presentation of structurally intact membrane proteins, divergent species (chickens) to generate antibodies against conserved epitopes, and optimized protocols for the isolation of rare antibodies, even for membrane proteins embedded in a lipid bilayer.

VeRSaMAbs are available for a wide range of protein targets across scientific fields, including immunology, oncology, and virology, and CSB's catalog will continue to expand as MAbs are validated. 

www.cellsurfacebio.com

Would you like to be featured on Startup Weekly for a free profile interview? Fill in this questionnaire here.

You can also send your columns / opinions / thought leadership pieces / industry insights, survey and reports to info@startup-weekly.com.